This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data From Merck’s Investigational Hepatitis C Treatment Portfolio To Be Presented At The 64th American Association For The Study Of Liver Diseases Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64 th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013.

“Merck is committed to developing HCV therapies that have the potential to offer new options for a broad range of patient types,” said Dr. Eliav Barr, vice president, Infectious Diseases, Merck Research Laboratories. “We continue to build upon our strong legacy in HCV and look forward to sharing the latest clinical data for our investigational HCV therapies, MK-5172 and MK-8742.”

MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor currently in Phase IIB development. MK-8742 is an investigational, once-daily, oral HCV NS5A replication complex inhibitor currently in Phase IIB development. Both candidates are being evaluated in broad clinical programs that include investigations in various HCV segments, multiple HCV genotypes and patients who have previously failed prior therapy.

Selected presentations of clinical data for MK-5172 and MK-8742

  • High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study. Lawitz, E., et al. Oral Presentation #76: Sunday, Nov. 3, 2013, 5:30-5:45 p.m.
  • Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release. McGivern, D.R., et al. Oral Presentation #78: Sunday, Nov. 3, 2013, 6:00-6:15 p.m.
  • High Efficacy at Lower Doses of MK-5172 25mg and 50mg Daily for 12 weeks in HCV Genotype (G) 1 Treatment-Naïve Non-Cirrhotic Patients. Vierling, J., N et al. Poster #1123. Sunday, Nov. 3, 2013, 8:00 a.m. to 5:30 p.m.
  • Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects with HCV GT1 Infection: The C-SPIRIT Study. Gane, E.J., et al., Poster #1110. Sunday, Nov. 3, 2013, 8:00 a.m. to 5:30 p.m.
  • MK-8742, a HCV NS5A Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients. Yeh, W. W., et al. Poster #479. Saturday, Nov. 2, 2013, 2:00-7:30 p.m.

The abstracts were published today and can be accessed on the AASLD website. For program information, please visit: http://www.aasld.org/livermeeting/program/Pages/default.aspx

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs